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OBJECTIVE — The aim of this study was to describe the natural history of insulin secretion
and insulin sensitivity in the development of isolated impaired fasting glycemia (i-IFG), isolated
impaired glucose tolerance (i-IGT), and combined IFG/IGT.
RESEARCH DESIGN AND METHODS — Baseline and 5-year follow-up data from the
Inter99studywereused.Individualswithnormalglucosetolerance(NGT)atbaselineandi-IFG,
i-IGT, combined IFG/IGT, or NGT at the 5-year follow-up were examined with an oral glucose
tolerance test (n  3,145). Insulin sensitivity index (ISI), homeostasis model assessment of
insulin sensitivity (HOMA-IS), early-phase insulin release (EPIR), and insulin secretion relative
to insulin action (disposition index) were estimated.
RESULTS — Five years before the pre-diabetes diagnoses (i-IFG, i-IGT, and IFG/IGT), ISI,
HOMA-IS, EPIR, and disposition index were lower than in individuals who maintained NGT.
Duringthe5-yearfollow-up,individualsdevelopingi-IFGexperiencedasigniﬁcantdeclineonly
inHOMA-IS,whereasindividualsdevelopingi-IGTexperiencedsigniﬁcantdeclinesinISI,EPIR,
and disposition index. Individuals with IFG/IGT exhibited pronounced declines in ISI, HOMA-
IS, EPIR, and disposition index during the 5-year follow-up.
CONCLUSIONS — Astationaryreducedinsulinsecretionfollowedbyadeclineinprimarily
hepatic insulin sensitivity characterizes the transition from NGT to i-IFG. In contrast, low
whole-body insulin sensitivity with a secondary lack of -cell compensation is associated with
the development of i-IGT. Thereby, i-IFG and i-IGT appear to result from different underlying
mechanisms, which may have implications for the prevention and treatment of the diabetes that
succeeds them.
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D
uring the past few years, it has been
established that the pre-diabetic
conditions of isolated impaired
fasting glycemia (i-IFG), isolated im-
paired glucose tolerance (i-IGT), and
combined fasting and postchallenge hy-
perglycemia (IFG/IGT) represent distinct
pathways to diabetes. These pre-diabetic
states are characterized by different de-
grees of insulin sensitivity, insulin secre-
tion,andhepaticglucoseoutputaswellas
secretion of glucagon and incretin hor-
mones (1–8). Nevertheless, the primary
abnormalities inherent in the different
pre-diabetic conditions are still un-
known.
Randomized trials have shown bene-
ﬁcialeffectsoflifestyleinterventionondi-
abetes risk in individuals with i-IGT and
IFG/IGT (9,10), but whether lifestyle in-
terventions have the same preventive ef-
fects in individuals with i-IFG is not
known. Indeed, a more profound insight
into the pathogenesis of the disease is
needed to optimize prevention and treat-
ment of type 2 diabetes. In particular, fo-
cus on the initial defects responsible for
hyperglycemia in the fasting and post-
prandialstatesisessentialforinterrupting
the progression from normal to abnormal
glucose metabolism.
Most previous studies have examined
the pathophysiology of pre-diabetes in
cross-sectional settings without knowing
the time of onset of glycemic abnormali-
ties.However,theobservedabnormalities
in pre-diabetes may be related to traits
already apparent in the normoglycemic
state. Prospective studies are therefore
needed to clarify whether this is the case
or whether the metabolic abnormalities
associatedwithi-IFG,i-IGT,andIFG/IGT
develop simultaneously with the in-
creases in fasting and/or postchallenge
plasma glucose levels.
The aim of this study was to de-
scribe the natural history of insulin sen-
sitivity and insulin secretion during the
progression from normal glucose toler-
ance (NGT) to the pre-diabetic states of
i-IFG, i-IGT, and combined IFG/IGT.
RESEARCH DESIGN AND
METHODS— Individuals from the
Danish population-based study Inter99
(11) were used as the study population.
TheInter99studyisa5-yearnonpharma-
cological intervention study with the aim
of reducing the incidence of ischemic
heart disease and type 2 diabetes in the
Danish population.
All individuals were invited to a
screeningprogramattheResearchCentre
for Prevention and Health in Glostrup in
1999–2001. At baseline, 6,784 subjects
were included in the Inter99 study
(52.5% of the invited subjects). After 5
years, all eligible 6,784 individuals were
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of 4,735 individuals were classiﬁed as
having NGT at baseline, and 68.2% of
these (n  3,229) attended the 5-year fol-
low-up examination. Individuals with di-
abetes at the 5-year follow-up (n  42) or
with incomplete measures of fasting
plasma glucose (FPG) or 2-h plasma glu-
cose (n  42) were excluded, leaving
3,145 individuals with baseline and
5-year follow-up data for analysis.
All participants gave written in-
formed consent before taking part in the
Inter99 study. The protocol was in accor-
dance with the Helsinki Declaration, ap-
proved by the local ethics committee (KA
98 155), and registered as a clinical trial.
The Inter99 study is described in detail
elsewhere (11,12).
Glucose tolerance status
After an overnight fast, the participants
hadastandard75-goralglucosetolerance
test (OGTT). Venous samples for mea-
surement of plasma glucose and serum
insulin concentrations were taken before
glucose ingestion and after 30 and 120
min.Glucosewasanalyzedusingthehex-
okinase/G6P-DH technique (Boehringer
Mannheim, Mannheim, Germany), and
insulin was analyzed with the ﬂuoroim-
munoassay technique (AutoDELFIA; Per-
kin Elmer-Wallac, Turku, Finland). The
participants were classiﬁed into catego-
ries of glucose tolerance according to the
World Health Organization 1999 criteria
(13).
Data collection
Self-administered general questionnaires
were completed before the participants’
ﬁrst visit to the research center. Family
history of diabetes was assessed by asking
questionsaboutparents’andsiblings’his-
tories of diabetes. An estimate of physical
activityinminutesperweekwasobtained
by combining answers of commuting and
leisure-time physical activity (14). Smok-
ing status was categorized as follows:
dailysmokers,occasionalsmokers,previ-
ous smokers, and never smokers. A 48-
item food-frequency questionnaire was
used to assess the participants’ dietary
habits.Basedontheparticipants’intakeof
vegetables, fruit, ﬁsh, and fat, a dietary
quality score ranging from 1 (unhealthy
dietary habits) to 9 (healthy dietary hab-
its) was developed (15). Measurement of
waist circumference was taken to the
nearest 0.5 cm halfway between the low-
est point of the costal margin and highest
point of the iliac crest.
Lifestyle intervention
All participants received individual life-
style counseling, including a risk assess-
ment based on age, sex, total and HDL
cholesterol, systolic blood pressure,
smoking, BMI, known diabetes, family
predisposition, and previous heart dis-
ease (16). Individuals at high risk of de-
veloping ischemic heart disease were
offered a low- or high-intensity lifestyle in-
tervention at baseline. Individuals in the
high-intensity intervention group were of-
feredparticipationingroupmeetingswitha
clinical dietitian. The aim of the meetings
was to increase the participants’ knowledge
regarding the importance of smoking, diet,
and physical activity in the prevention of
type 2 diabetes and cardiovascular dis-
eases. Participants in the low-intensity in-
tervention group were only referred to
their general practitioner. The random-
ization and intervention are described in
detail elsewhere (11,12). A three-class
variable based on the risk and interven-
tion status (low-risk/no intervention,
high-risk/low-intensity intervention, and
high-risk/high-intensity intervention)
was included in the present analyses, to-
gether with changes in different lifestyle
factors, to adjust for a potential effect of
the intervention.
Calculations
Insulinsensitivitywasestimatedbyuseof
theinsulinsensitivityindex(ISI),whichis
basedonplasmaglucoseandinsulinmea-
surementsduringOGTTsaswellasinfor-
mation on body weight (17). The ISI
correlates relatively well with the M value
from a euglycemic-hyperinsulinemic
clamp (17). Homeostasis model assess-
ment (HOMA) of insulin sensitivity
(HOMA-IS) (1/HOMA of insulin resis-
tance) was also calculated (18). Early-
phase insulin release (EPIR) was
estimatedfromfastinginsulin,30-minin-
sulin, and 30-min plasma glucose levels
(19). EPIR correlates with ﬁrst-phase in-
sulinreleasemeasuredduringahypergly-
cemic-hyperinsulinemic clamp. An
estimateofdispositionindex(DI)wascal-
culated by multiplying ISI with EPIR.
Hence, DI reﬂects the ability of the -cell
to compensate for insulin resistance.
When ISI was plotted against EPIR, the
data points approximated a hyperbolic
curve, suggesting that DI may be a good
surrogate measure of -cell function.
Statistical methods
The study population was divided into
four groups of glucose tolerance based on
the classiﬁcation at the 5-year follow-up:
1) NGT, 2) incident i-IFG, 3) incident i-
IGT, and 4) incident IFG/IGT. Estimates
ofISI,HOMA-IS,EPIR,andDIwerecom-
pared among the four groups before the
diagnosis (baseline, all had NGT) and at
the time of diagnosis (5-year follow-up)
by use of the Wald test from multiple lin-
ear regression models. Changes in meta-
bolic characteristics during the 5-year
follow-up (5-year follow-up minus
baseline) were also analyzed in multiple
linear regression models. Serum insulin
levels, HOMA-IS, ISI, and DI were non-
normally distributed and therefore were
log-transformed before analysis. SAS
(version9.1;SASInstitute,Cary,NC)was
used for statistical analysis.
Even though a relatively large num-
ber of statistical comparisons were per-
formed in this study, we did not use P
corrections, because the majority of the
tests were predeﬁned. Thus, some of the
borderline and weakly signiﬁcant ﬁnd-
ings may be related to noncausal associa-
tions and should be interpreted with
some caution.
RESULTS
Before the pre-diabetes diagnosis
(baseline)
Five years before the development of pre-
diabetes, several characteristics differed
among the groups (Table 1). The propor-
tion of men and individuals with a family
history of diabetes was highest in the
groups who later developed i-IFG and
IFG/IGT. Physical activity was lower in
those who later developed i-IGT, and di-
etaryqualityscorewaslowerinallgroups
progressing to pre-diabetes but only sig-
niﬁcant in those with subsequent i-IGT.
At baseline, plasma glucose and insulin
levels were higher, and ISI, HOMA-IS,
EPIR, and DI were lower in individuals
who progressed to i-IFG, i-IGT, or IFG/
IGT than in those who maintained NGT
status. Those who later progressed to i-
IGT had lower baseline ISI than those
who subsequently developed i-IFG. In
contrast, baseline EPIR was slightly but
signiﬁcantly lower in those with subse-
quent i-IFG and IFG/IGT than in those
who later developed i-IGT (Table 1).
High-intensity lifestyle intervention
was offered to 36.6% of those who main-
tained NGT status, 50.6% of those who
developed i-IFG, 39.1% of those who de-
veloped i-IGT, and 46.4% of those who
developed IFG/IGT (P  0.05 for i-IFG
versus NGT).
Progression from NGT to IFG and IGT
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(5-year follow-up)
Atthe5-yearexamination,ISI,HOMA-IS,
EPIR, and DI were still low in all three
pre-diabetic groups (Table 2). However,
ISI was lower in individuals with i-IGT
and IFG/IGT than in those with i-IFG,
whereas HOMA-IS was lower in individ-
ualswithi-IFGandIFG/IGTthaninthose
with i-IGT. EPIR was equally low in indi-
vidualswithi-IFGandi-IGT,butlowerin
those with IFG/IGT. DI was lower in in-
dividuals with i-IGT and IFG/IGT than in
those with i-IFG.
Cross-sectional data of all individuals
with NGT, i-IFG, i-IGT, and IFG/IGT at
baseline in the Inter99 study (n  6,006)
showedthesamepatternofinsulinsensitiv-
ity and insulin secretion (supplemental Ta-
ble A1, available in an online appendix at
http://dx.doi.org/10.2337/dc08-1195).
Transition from normal to abnormal
glucose regulation (5-year changes)
During the 5-year follow-up, different
changes in insulin secretion and insulin
sensitivity were observed in the groups
developing i-IFG, i-IGT, and IFG/IGT
compared with those who maintained
NGT status (Fig. 1). ISI decreased signif-
icantlyinindividualsprogressingtoi-IGT
and IFG/IGT but not in those who devel-
oped i-IFG even though ISI tended to fall
(P0.227vs.NGT;Fig.1A).Incontrast,
HOMA-IS decreased signiﬁcantly in indi-
vidualswithi-IFGandIFG/IGTbutnotin
thosewithi-IGT(P0.851vs.NGT;Fig.
1B). A minor but signiﬁcant decline in
EPIR was observed for individuals with
i-IGT compared with those with NGT
(P  0.001; Fig. 1C). The change in EPIR
did not differ among the other pre-
diabetes groups and the NGT group (P 
0.154 for all other comparisons), even
though EPIR seemed to increase in the
Table 1—Characteristics of individuals with NGT before development of i-IFG, i-IGT, or IFG/IGT or maintenance of NGT status
NGT 3 NGT NGT 3 i-IFG NGT 3 i-IGT NGT 3 IFG/IGT P  0.05*
n 2,842 83 192 28
Male sex (%) 46.8 (45.0–48.7) 77.1 (66.6–85.6) 53.1 (45.8–60.3) 67.9 (47.6–84.1) a, c, d
Family history of diabetes (%) 14.4 (13.2–15.8) 22.9 (14.4–33.4) 18.2 (13.0–24.4) 39.3 (21.5;59.4) a, c, e, f
Age (years) 45.4 (45.2–45.7) 48.6 (47.0–50.2) 47.7 (46.6–48.7) 49.0 (46.2–51.8) a, b, c
BMI (kg/m
2) 25.2 (25.1–25.3) 27.2 (26.4–28.1) 26.4 (25.9–27.0) 28.2 (26.7–29.6) a, b, c, f
Waist circumference (cm) 83.4 (82.9–83.8) 92.3 (89.8–94.8) 87.6 (85.9–89.2) 95.4 (91.1–99.7) a, b, c, e, f
Physical activity (min/week) 305 (299–312) 295 (260–331) 275 (251–298) 336 (276–396) b
Dietary quality score (points) 4.08 (4.03–4.14) 3.69 (3.37–4.00) 3.84 (3.63–4.04) 3.64 (3.11–4.17) b
Fasting plasma glucose (mmol/l) 5.3 (5.3–5.3) 5.7 (5.6–5.8) 5.4 (5.3–5.4) 5.8 (5.6–5.9) a, c, d, f
2-h plasma glucose (mmol/l) 5.4 (5.4–5.5) 5.8 (5.6–6.0) 6.2 (6.0–6.3) 6.4 (6.0–6.8) a, b, c, d, e
Fasting serum insulin (pmol/l)† 30 (21–43) 38 (26–48) 35 (24–56) 34 (24–59) a, b
2-h serum insulin (pmol/l)† 131 (83–196) 148 (77–266) 188 (124–284) 161 (86–341) a, b, c, d
ISI† 2.64 (2.16–3.30) 2.27 (1.85–3.00) 2.13 (1.85–2.51) 2.14 (1.63–3.02) a, b, c, d
HOMA-IS† 0.99 (0.67–1.42) 0.74 (0.58–1.08) 0.81 (0.51–1.20) 0.78 (0.48–1.11) a, b
EPIR† 755 (559–973) 637 (449–912) 689 (494–1,014) 501 (364–936) a, c, d, f
DI† 2,037 (1,464–2,728) 1,507 (1,053–2,175) 1,586 (1,112–2,182) 1,209 (699–1,620) a, b, c
Data are unadjusted means and proportions (95% CI) unless otherwise indicated. Baseline, n  3,145. P values are adjusted for age and sex. *P values for BMI were
further adjusted for baseline physical activity level. P values for HOMA-IS, ISI, EPIR, and DI were further adjusted for family history of diabetes as well as baseline
values of BMI, smoking, physical activity, and dietary quality. Wald test from linear models: a, i-IFG vs. NGT; b, i-IGT vs. NGT; c, IFG/IGT vs. NGT; d, i-IGT vs.
i-IFG; e, IFG/IGT vs. i-IFG; f, IFG/IGT vs. i-IGT. †Unadjusted medians (interquartile range).
Table 2—Characteristics of individuals with incident i-IFG, i-IGT, IFG/IGT, or NGT (5-year follow-up)
NGT 3 NGT NGT 3 i-IFG NGT 3 i-IGT NGT 3 IFG/IGT P  0.05*
n 2,842 83 192 28
BMI (kg/m
2) 25.6 (25.5–25.8) 28.2 (27.4–29.1) 27.4 (26.8–27.9) 29.1 (27.6–30.6) a, b, c
Waist circumference (cm) 86.5 (86.1–86.9) 95.9 (93.4–98.5) 91.8 (90.1–93.5) 98.5 (94.1–102.9) a, b, c, f
Physical activity (min/week) 301 (296–307) 299 (265–333) 256 (233–279) 309 (250–368) b
Dietary quality score (points) 4.60 (4.54–4.65) 4.37 (4.06–4.69) 4.25 (4.04–4.46) 4.46 (3.89–5.03) b
Fasting plasma glucose (mmol/l) 5.2 (5.2–5.2) 6.4 (6.3–6.4) 5.4 (5.1–5.4) 6.4 (6.2–6.6) a, b, c, d, f
2-h plasma glucose (mmol/l) 5.2 (5.2–5.3) 5.8 (5.6–6.0) 8.6 (8.5–8.8) 8.5 (8.1–8.9) a, b, c, d, e
Fasting serum insulin (pmol/l)† 27 (20–39) 48 (34–67) 37 (25–54) 56 (37–91) a, b, c, d, f
2-h serum insulin (pmol/l)† 139 (85–211) 202 (103–292) 365 (231–560) 361 (246–571) a, b, c, d, e
ISI† 2.68 (2.19–3.43) 1.99 (1.69–2.54) 1.47 (1.27–1.67) 1.36 (1.20–1.58) a, b, c, d, e
HOMA-IS† 1.11 (0.75–1.54) 0.51 (0.36–0.73) 0.79 (0.54–1.17) 0.45 (0.33–0.67) a, b, c, d, f
EPIR† 746 (569–978) 639 (380–960) 670 (447–903) 586 (365–1,001) a, b, c, f
DI† 2,084 (1,514–2,864) 1,325 (918–1,949) 1,047 (656–1,312) 815 (516–1,185) a, b, c, d, e
Dataareunadjustedmeansandproportions(95%CI)unlessotherwiseindicated.n3,145.*Pvaluesareadjustedforage,sex,andrisk/interventiongroup.Pvalues
for BMI were further adjusted for 5-year physical activity level. P values for ISI, HOMA-IS, EPIR, and DI were further adjusted for family history of diabetes as well
as 5-year values of BMI, smoking, physical activity, and dietary quality. Wald test from linear models: a, i-IFG vs. NGT; b, i-IGT vs. NGT; c, IFG/IGT vs. NGT; d,
i-IGT vs. i-IFG; e, IFG/IGT vs. i-IFG; f, IFG/IGT vs. i-IGT. †Unadjusted medians (interquartile range).
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low-up (P  0.393 vs. NGT; Fig. 1C).
However,DIdecreasedsigniﬁcantlyinin-
dividuals who progressed to i-IGT and
IFG/IGT and tended to decrease in those
who developed i-IFG (P  0.066) (Fig.
1D).
CONCLUSIONS — This study is the
ﬁrst to report abnormalities in insulin se-
cretion and insulin sensitivity before the
development of i-IFG, i-IGT, and IFG/
IGT. We found that different distur-
bances of insulin sensitivity, absolute
insulin secretion, and insulin secretion
relative to insulin resistance were appar-
ent 5 years before the pre-diabetic states
of i-IFG, i-IGT, and IFG/IGT were
breached. These ﬁndings support the
view that i-IFG and i-IGT represent two
distinct pathological mechanisms.
Progression from NGT to i-IFG
Absolute and relative insulin secretion
(EPIRandDI)weresigniﬁcantlyimpaired
innormoglycemicindividualswhosubse-
quently progressed to i-IFG, but during
the development of i-IFG, EPIR and DI
did not decrease further, indicating that a
progressive loss of the ability to secrete
sufﬁcient amounts of insulin is not a ma-
jor feature in the early states of fasting
hyperglycemia. Instead, an underlying,
more stationary -cell failure seems to be
present in these individuals. Reduced ab-
solute and/or relative insulin secretion
has previously been demonstrated in in-
dividuals with i-IFG (1,2,5,6,20). How-
ever, all of these studies were cross-
sectional, and they were therefore not
able to detect whether this feature oc-
curred concomitantly with the develop-
ment of hyperglycemia or whether it was
manifest years before overt hyperglyce-
mia was present. In this particular study,
family history of diabetes was signiﬁ-
cantly more prevalent in individuals with
i-IFG than in those with NGT. This ﬁnd-
ingcouldindicatearoleforgeneticsinthe
development of i-IFG, which should be
examined in future studies.
Priortothedevelopmentofi-IFGand
at time of diagnosis, ISI was signiﬁcantly
reduced compared with that in individu-
als with NGT, but ISI did not change sig-
niﬁcantly during the development of
i-IFG.Theﬁndingofreducedinsulinsen-
sitivity contrasts with recent observations
inasmallersubsampleoftheInter99pop-
ulation studied with the euglycemic-
hyperinsulinemicclamptechnique(1).In
addition, other studies using the euglyce-
mic-hyperinsulinemic clamp technique
have reported normal peripheral insulin
sensitivity in individuals with i-IFG
(1,4,6,7), whereas only a few studies re-
ported low insulin sensitivity (2,3). Ac-
cordingly, the low insulin sensitivity we
observed in individuals with i-IFG may
indicate that estimates of insulin sensitiv-
ityderivedfromOGTTsarenotasprecise
as measures obtained from “gold stan-
dards”suchastheeuglycemic-hyperinsu-
linemic clamp technique. The clamp
technique provides estimates of predom-
inantly peripheral (muscle) insulin action
and only to a lesser extent hepatic insulin
action. Whether estimates based on glu-
coseandinsulinlevelsduringOGTTsalso
reﬂect mainly peripheral insulin sensitiv-
ity needs to be addressed in future stud-
ies. HOMA-IS is based on fasting glucose
and insulin levels and therefore is as-
sumedtoreﬂecthepaticinsulinsensitivity
(5). The pre-diabetic state, i-IFG, there-
fore appears to be caused by stationary
abnormalities in -cell function in com-
bination with a progressive decline in he-
patic insulin sensitivity.
In the present study, the proportion
ofmenwas65%higherinthei-IFGgroup
than in the group with NGT. A higher
prevalenceofi-IFGinmenhaspreviously
been reported by others (8,20,21). Be-
cause men in general have lower serum
insulin levels than women (20), the dif-
ferent sex distributions in the i-IFG and
i-IGT groups may have contributed to
some of the observed differences in insu-
lin secretion between the groups. Further
studies are needed to clarify the impact of
sex differences on the pathophysiology of
i-IFG and i-IGT.
Progression from NGT to i-IGT
Five years prior to the i-IGT diagnosis,
EPIR was not signiﬁcantly different from
thatinthosewhomaintainedNGTstatus.
However, during the development of i-
IGT,smallbutsigniﬁcantdeclinesinEPIR
and DI were observed. This ﬁnding indi-
cates that a progressive, and thereby age-
dependent, loss of insulin secretion is
involved in the development of postchal-
lenge hyperglycemia. Indeed, age-
dependent loss of insulin secretion is a
well-establishedfeatureofoverttype2di-
abetes as documented in the UK Prospec-
tiveDiabetesStudy(22).Thepresentdata
indicate that this feature may be more
central to patients who have developed
type 2 diabetes via i-IGT compared with
via i-IFG, but this suggestion remains to
be shown in prospective studies includ-
ing patients with overt type 2 diabetes
Figure 1—Baseline and 5-year values of ISI (A), HOMA-IS (B), EPIR (C), and DI (D) in 3,145
individuals developing i-IFG ( ), i-IGT (‚), or IFG/IGT (E) or maintaining NGT status ( ).
Data are presented as medians. P values for differences in changes (5-year minus baseline)
betweengroupsareadjustedforage,sex,familyhistoryofdiabetes,andrisk/interventiongroupas
well as for changes in BMI, smoking, physical activity, and dietary quality during the 5 years of
follow-up. Wald test from linear models (P  0.05): a, i-IFG vs. NGT; b, i-IGT vs. NGT; c,
IFG/IGT vs. NGT; d, i-IGT vs. i-IFG, e, IFG/IGT vs. i-IFG; f, IFG/IGT vs. i-IGT.
Progression from NGT to IFG and IGT
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diagnosis.
Numerous cross-sectional studies
showedthatindividualswithi-IGTarein-
sulin resistant (1–7). In this study, we
take this ﬁnding a step further by docu-
menting that low insulin sensitivity is
presentalready5yearsbeforethedemon-
stration of i-IGT. The progressive decline
of insulin secretion therefore seems to be
secondary to the low insulin sensitivity
and thus represents an inadequate com-
pensatory insulin secretory response.
This primary decline in insulin sensitivity
could be caused by an adverse lifestyle, as
indicated by the lower levels of physical
activity and dietary quality compared
with those for individuals with NGT.
However, genetic factors or in utero pre-
programmed abnormalities could also
have contributed.
Progression from NGT to IFG/IGT
Not surprisingly, the IFG/IGT phenotype
was characterized by the same abnormal-
ities in insulin sensitivity as seen in those
who developed i-IFG (decline in HOMA-
IS) and i-IGT (decline in ISI). Interest-
ingly, EPIR tended to increase during the
development of IFG/IGT. This ﬁnding
supportsthenotionthatmodestincreases
in plasma glucose levels may induce
-cell proliferation and survival, whereas
prolonged exposure to signiﬁcant eleva-
tions in plasma glucose levels can cause
impaired -cell proliferation and in-
creased -cell failure and apoptosis (23).
Based on our observations, we suggest
that some of the mechanisms leading to
an early compensatory increase in -cell
functionmaybeinitiatedbyelevatedfast-
ing plasma glucose (i-IFG and IFG/IGT)
but not by postprandial plasma glucose
levels (i-IGT). In that respect, it was of
interest that individuals who developed
IFG/IGThadmorecharacteristicsincom-
mon with those who developed i-IFG
than with those who developed i-IGT
(e.g., sex distribution and family history
of diabetes). We therefore suggest that in-
dividuals with elevated 2-h plasma glu-
cose levels should be separated into an
i-IGT and an IFG/IGT group instead of
being classiﬁed in one group of IGT indi-
viduals as currently suggested by the
World Health Organization (13).
Study limitations
Our estimates of insulin secretion and in-
sulin sensitivity were based on OGTTs
and therefore may correlate with the clas-
siﬁcation of the pre-diabetic groups. In
addition, it should be noted that disposi-
tion indexes based on estimates of insulin
secretion and insulin sensitivity derived
from the same test (e.g., an OGTT) may
not be as solid and reliable as disposition
indexes based on independent tests. Ide-
ally, estimates of insulin secretion and ac-
tion should be based on “gold standard”
testssuchastheglucoseclamptechnique.
However, this is not feasible in large-scale
epidemiological studies, and we believe
that proxy measures are reliable with
large datasets such as that in this study.
However, caution should be taken when
one is comparing estimates of insulin se-
cretion based on intravenous versus oral
glucose tolerance tests. In particular, the
gut incretin hormones glucagon-like-
peptide-1 and glucose-dependent insuli-
notropic polypeptide may inﬂuence the
results,becausethesecretionofthesehor-
monesseemstodiffersigniﬁcantlyamong
individuals with different types of pre-
diabetes (1).
Theclassiﬁcationofglucosetolerance
status was based on single OGTTs. Ac-
cordingly, it is likely that some individu-
als may have been misclassiﬁed because
ofnormalday-to-dayvariationsinplasma
glucose. In addition, the intraindividual
variation in serum insulin levels is large
(24), affecting the estimates of insulin se-
cretion and action. Small changes in the
estimates would therefore be expected if
thesamemeasurementswererepeatedon
a separate day.
In general, the changes in insulin se-
cretion and insulin sensitivity during the
5-year follow-up were relatively small.
However, because even small changes in
plasma glucose and insulin levels may
haveconsequencesforglucosehomeosta-
sis, we believe our ﬁndings are biologi-
callyrelevant.Nevertheless,thebiological
signiﬁcance of such small disturbances
needs to be clariﬁed in other studies.
Finally, it is possible that individuals
who participated in group lifestyle coun-
seling (high-intensity intervention) may
have changed their physical activity level,
smoking status, diet, and body composi-
tion more than those who were not in-
cluded in the high-intensity intervention
duringthe5-yearfollow-up.However,by
adjustingforinterventionstatusaswellas
for changes in body composition and life-
style factors, we believe that our results
are reliable and can be generalized to
other white Caucasian populations.
In summary, this study showed that
impairmentsinglucosemetabolismoccur
many years before it is possible to classify
individuals as abnormally hyperglycemic
eitherinthefastingorpostchallengestate.
Hyperglycemia in the fasting state (i-IFG)
seems primarily to be caused by an inher-
ent insulin secretory dysfunction fol-
lowed by a decline in hepatic insulin
sensitivity. In contrast, the development
of postchallenge hyperglycemia (i-IGT)
mainly seems to be caused by low whole-
bodyinsulinsensitivityfollowedbyapro-
gressive decline in -cell function,
indicating a loss of -cell compensation.
This study supports the notion that the
pre-diabeticstatesofi-IFGandi-IGTmay
have different etiological and pathophys-
iological origins, which in turn may have
implications for future prevention and
treatment of overt type 2 diabetes.
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